Publikace

Laboratoř nádorové imunologie

Metastatic spread inhibition of cancer cells through stimuli-sensitive HPMA copolymer-bound actinonin nanomedicines

HPMA copolymer mebendazole conjugate allows systemic administration and possesses antitumour activity in vivo

Simultaneous delivery of doxorubicin and protease inhibitor derivative to solid tumors via star-shaped polymer nanomedicines overcomes P-gp- and STAT3-mediated chemoresistance

HPMA-based copolymers carrying STAT3 inhibitor cucurbitacin-D as stimulus-sensitive nanomedicines for oncotherapy

IL-2/JES6-1 mAb complexes dramatically increase sensitivity to LPS through IFN-gamma production by CD25(+)Foxp3(-) T cells

Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients

Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling

Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients

Blokový kopolymer pro překonání lékové rezistence nádorů k chemoterapii; jeho polymerní konjugát s léčivem; farmaceutická kompozice je obsahující; způsob jejich přípravy a jejich použití

1
2
3